MedTrace Logo

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00081263 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2017-09-15

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies how well celecoxib works in treating patients with cervical intraepithelial neoplasia, a precancerous lesion of the cervix which can develop into cervical cancer. Celecoxib may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia.

Conditions

  • Cervical Carcinoma
  • Cervical Intraepithelial Neoplasia Grade 2/3
  • Stage 0 Cervical Cancer

Interventions

DRUG

Celecoxib

Given orally

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Given orally

Sponsors & Collaborators

  • Gynecologic Oncology Group

    lead NETWORK

  • National Cancer Institute (NCI)

    collaborator NIH

Principal Investigators

  • Janet Rader · NRG Oncology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00081263 on ClinicalTrials.gov